The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML

por Novotny-Diermayr, V, Hart, S, Goh, K C, Cheong, A, Ong, L-C, Hentze, H, Pasha, M K, Jayaraman, R, Ethirajulu, K, Wood, J M
Publicado 2012

Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia

por Hart, S, Goh, K C, Novotny-Diermayr, V, Tan, Y C, Madan, B, Amalini, C, Ong, L C, Kheng, B, Cheong, A, Zhou, J, Chng, W J, Wood, J M
Publicado 2011